Please enter the email address you used to register, then we will send you a link to choose a new password
- Form 8-K
Cara Therapeutics plans to explore strategic alternatives. There are no meaningful development programs in the pipeline, analys...
Canaccord Genuity analyst Sumant Kulkarni downgrades Cara Therapeutics (NASDAQ:CARA) from Buy to Hold and lowers the price t...
HC Wainwright & Co. analyst Oren Livnat downgrades Cara Therapeutics (NASDAQ:CARA) from Buy to Neutral.
Needham analyst Joseph Stringer downgrades Cara Therapeutics (NASDAQ:CARA) from Buy to Hold.
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – Company will discontinue clinical pr...